Trial Profile

A Phase III trial of Ivonescimab(AK112) for the first-line treatment of PD-L1positive NSCLC

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivonescimab (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors Akeso Biopharma

Most Recent Events

01 Feb 2022 New trial record
30 Jan 2022 According to an Akeso Biopharma media release, this study will commence soon.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com